Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
We are seeking a Central Operations Head (COH) to provide strategic leadership across clinical drug supply, Clinical Trial Agreement (CTA), and eTMF management to support global clinical development programs. This role partners cross-functionally with Clinical, Regulatory, Legal, Technical Operations, and Operational Excellence to ensure alignment on trial needs, risk management, and execution priorities.
You will oversee end-to-end delivery across trials, define outsourcing and vendor strategies, and ensure performance through KPIs, KRIs, and governance. This role is accountable for driving operational excellence, ensuring inspection readiness, and maintaining compliance with global regulations and internal standards.
As a leader, you will build and develop a high-performing team, establish scalable processes and best practices, and foster a culture of accountability, innovation, and continuous improvement in a fast-paced biotech environment.
Your role
- Provide strategic direction for clinical drug supply management, clinical trial agreement (CTA) management, and eTMF management activities to support clinical development objectives across all programs and trials
- Collaborate with Trial Management, Regulatory Affairs, Clinical Development, Legal, and Technical Operations to align on trial needs and deliverables
- Collaborate with Operational Excellence & Clinical Compliance and GMP compliance to align on risk assessment, metrics, KPIs, and KRIs for management of clinical drug supply, CTAs, and eTMF
- Define and implement outsourcing strategies (incl. Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs) and vendors) in partnership with VP of Global Clinical Operations and Head of Clinical Sourcing & Contracting
- Define functional goals, performance metrics, and resourcing strategies. Drive innovation including adoption of risk-based approaches
- Oversee end-to-end execution of drug supply-/ CTA-/ and eTMF management across clinical trials, ensuring timely, high-quality, and inspection-ready deliverables
- Track CRO, CMO, and vendor performance using metrics, KPIs, and KRIs; lead SMO governance meetings to address escalated issues and drive continuous improvement
- Establish and maintain best practices and standards throughout the trial lifecycle
- Ensure adherence to global regulatory requirements, GCP and internal SOPs. Lead audit and inspection readiness for drug supply-/ CTA-/ and eTMF management and implement effective oversight models for internal teams and outsourced partners. Perform internal quality reviews and ensure inspection readiness of trial documentation
- Lead, coach, and develop a high-performing team. Foster a culture of collaboration, continuous learning, and accountability, while supporting career progression and succession planning across the function
- Select, manage, and govern external vendors. Define expectations, monitor performance via KPIs, and drive accountability through governance forums to ensure quality, timelines, and cost-effectiveness
What You Bring
- 12+ years of trial management experience with 5+ years in leadership position
- Bachelor’s degree in Life Sciences, Pharmacy or related field (required). Advanced degree, e.g., MS, PharmD, PhD, MBA (preferred)
- Significant experience working in global clinical development organization
- Significant experience in outsourcing and oversight
- Expert knowledge in ICH GCP and GMP
- Expert knowledge in computer technologies to plan, forecast, and track documents/ material on all levels
- Expert knowledge in risk assessment and management on program and trial-level
- Familiarity with clinical trial systems (e.g., CTMS, eTMF, IRT) and operational metrics, KPIs, and KRIs
- Familiarity with clinical supply planning, forecasting, and inventory tools
- Independent judgment and objectivity
- Strong analytical and influencing skills
- Ability to drive accountability across functions
- Strong leadership and interpersonal skills
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-Hybrid
Skills Required
- 12+ years of trial management experience
- 5+ years in a leadership position
- Bachelor's degree in Life Sciences, Pharmacy or related field
- Significant experience in global clinical development
- Expert knowledge in ICH GCP and GMP
- Familiarity with clinical trial systems
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
